1. Home
  2. RLMD vs MVBF Comparison

RLMD vs MVBF Comparison

Compare RLMD & MVBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • MVBF
  • Stock Information
  • Founded
  • RLMD 2004
  • MVBF 1997
  • Country
  • RLMD United States
  • MVBF United States
  • Employees
  • RLMD N/A
  • MVBF N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • MVBF Major Banks
  • Sector
  • RLMD Health Care
  • MVBF Finance
  • Exchange
  • RLMD Nasdaq
  • MVBF Nasdaq
  • Market Cap
  • RLMD 289.7M
  • MVBF 333.7M
  • IPO Year
  • RLMD N/A
  • MVBF N/A
  • Fundamental
  • Price
  • RLMD $4.22
  • MVBF $26.07
  • Analyst Decision
  • RLMD Buy
  • MVBF Strong Buy
  • Analyst Count
  • RLMD 2
  • MVBF 5
  • Target Price
  • RLMD $5.50
  • MVBF $27.60
  • AVG Volume (30 Days)
  • RLMD 2.1M
  • MVBF 37.8K
  • Earning Date
  • RLMD 11-13-2025
  • MVBF 10-29-2025
  • Dividend Yield
  • RLMD N/A
  • MVBF 2.61%
  • EPS Growth
  • RLMD N/A
  • MVBF 73.99
  • EPS
  • RLMD N/A
  • MVBF 2.45
  • Revenue
  • RLMD N/A
  • MVBF $167,853,000.00
  • Revenue This Year
  • RLMD N/A
  • MVBF N/A
  • Revenue Next Year
  • RLMD N/A
  • MVBF $12.76
  • P/E Ratio
  • RLMD N/A
  • MVBF $10.64
  • Revenue Growth
  • RLMD N/A
  • MVBF 18.75
  • 52 Week Low
  • RLMD $0.24
  • MVBF $15.59
  • 52 Week High
  • RLMD $5.12
  • MVBF $27.49
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 72.46
  • MVBF 53.06
  • Support Level
  • RLMD $3.81
  • MVBF $25.50
  • Resistance Level
  • RLMD $5.12
  • MVBF $26.15
  • Average True Range (ATR)
  • RLMD 0.55
  • MVBF 0.47
  • MACD
  • RLMD 0.05
  • MVBF -0.06
  • Stochastic Oscillator
  • RLMD 64.44
  • MVBF 54.26

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About MVBF MVB Financial Corp.

MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.

Share on Social Networks: